Nykode Therapeutics (Vaccibody) småprat (NYKD)

[Pk2k]

Hvorfor kan de ikke offentliggjøre det?

[HBA]

Det er slik selskapet selv har forklart det.

Men, sjekk gjerne selv:
Contact for Nykode Therapeutics ASA:
IR@nykode.com

[TekBot]

Nykode Therapeutics receives draft recommendation from Secretariat of Tax Appeal Board in pending tax case

• Draft recommendation for the appeal to be resolved in favor of Nykode.

• Appeal is still subject to a final recommendation from the Secretariat and subsequent decision from the Tax Appeal Board, expected within the next two months.
…

Vis børsmeldingen

• In the event of a final decision in line with the draft recommendation from the Secretariat, Nykode expects to be refunded NOK 325 million (plus applicable interest) from the Norwegian Tax Administration.

Oslo, Norway, August 26, 2026 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has received a draft recommendation from the Secretariat of the Norwegian Tax Appeal Board (Norw: Skatteklagenemda) relating to the pending tax case. The Tax Appeal Board is an independent administrative appeal body, with its own secretariat consisting of case handlers who prepare the case for and make recommendations to the Tax Appeal Board.

Reference is made to the ongoing tax case with the Norwegian Tax Administration (Norw: Skatteetaten) relating to the tax treatment of up-front payments received under a license agreement entered into in 2020. In October 2023, Nykode received a decision from the Norwegian Tax Administration, whereby the up-front payments were re-classified as taxable income in full in 2020. The decision triggered a tax payable of NOK 325 million. Nykode continues to believe that its assessment of the tax treatment is correct, which is also supported by several third-party tax experts, and the decision was appealed by Nykode to the Tax Appeal Board. As required under Norwegian law, the tax payable was settled pending an outcome of the appeal.

Nykode has today received a draft recommendation from the Secretariat of the Tax Appeal Board relating to the appeal. In the draft, the Secretariat agrees with Nykode’s assessment of the tax treatment of the up-front payments and recommends for the appeal to be resolved in favor of Nykode. The appeal is still subject to a final recommendation from the Secretariat and subsequent decision from the Tax Appeal Board, which is expected within the next two months.

In the event of a final decision in line with the draft recommendation from the Secretariat, Nykode expects to be refunded NOK 325 million (plus applicable interest) from the Norwegian Tax Administration.

As previously communicated, Nykode has an estimated cash runway into 2028, extending to 2029 pending a final positive outcome of the tax case.

Nykode will revert with an update once the outcome of the appeal is final.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in head and neck cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Harald Gurvin, CFO at Nykode Therapeutics ASA, on August 26, 2026 at 15:15 CET.

Kilde

[Boms]

Bra, jeg har som tidligere nevnt tro på at dagens ledelse i skatteklagenemda er mer uavhengige av Finansdepartementet som alltid ønsker seg mest mulig skatt. !!!

[Pk2k]

Deilig!!! For en hånd de har i kommende partner diskusjoner

[TraderJoe]

Er helt supert dette. Dersom dette står seg, vil Nykode få utbetalt ca. 370 MNOK. Selskapet skal kompenseres for for tapt rente på de midlene- ca. 50 MNOK for perioden.

Nykode har orden i sysakene - deilig at Skattetaten får en smekk på lanken.

[Procon]

Dette er fantastisk! Meget fint om det blir påfyll av likviditet fremover, når det nå forhandles om avtaler både her og der…

Er det noen som vet om hvordan Skatteetaten har argumentert? Altså i de fleste tilfeller er det jo steile fronter, men noen ganger kan, og særlig når staten er motpart, kan man endre standpunkt.

[TraderJoe]

Argumentasjonen har vel vært at upfront fee i lisensavtalen er skattbar inntekt ved inngåelse av avtalen - dvs. avvike fra sammenstillingsprinsippet ( Kostnader skal knyttes til og føres i samme periode som inntektene de er med på å skape.) Nykode har argumentert for at upfront fee også er knyttet til utviklingsløpet for VB.10.NEO - dvs. at upfront fee bør periodiseres i tak med utviklingskostnadene Nykode har hatt i perioden.

Med forbehold om at jeg ikke er skattespesialist

[Dreamliner]

Det var gøy med skattesaken i 10 minutter.

[Boms]

Må være mange bevisstløse selgere i den aksjen i dag, helt utrolig

[myk]

Det er tunge shortere som ble tatt med buksene nede

[Pk2k]

Ser ingen synlige shortere

[tverilytt]

Hvordan ser de ut?

[Procon]

Om ikke annet positivt at mange aksjer flytter hender. Er det sell on news av utålmodige aksjonærer?

[myk]

De er skumle og har sorte solbriller.
Denne saken har en verdi på over 1 nok per aksje?

[solskimm]

Litt over 1,- pr aksje, men det bør fjerne “emisjonsrabatten” som ligger i aksjen.

[Procon]

Takk for svar. Jeg er kjent med problemstillingen, men tenkte mer om om skatteetaten har beveget seg siden vedtaket i 2023. Vært tross alt en del korrespondanse mellom partene siden den tid. Jeg har vært overrasket over at selskapet har virket positive til medhold, og det kan jo ha kommet fra innrømmelser fra Skatteetaten. Ikke at jeg vet noe mer enn andre…

[beholdning]

Fra AI:

For 2024 er det rapportert at Skatteklagenemnda avvek fra sekretariatets innstilling i bare omtrent 2 prosent av sakene. Det innebærer grovt regnet at innstillingen ble fulgt i rundt 98 prosent av sakene.

[Do2Do]

@myk

tunge shortere

Ingen tunge nok til å være short over 0,5% (ca 1,5 mill aksjer)

[tverilytt]

DNB Carnegies anbefaling på MPC og Nykode ‎- DNB Nyheter